Syntara has added a new blood cancer indication to the clinical development plans for its drug discovery SNT-5505. The drug will be trialled along with chemotherapy in patients with low and intermediate risk of myelodysplastic syndrome (MDS). The trial, which has attracted a government research grant, will commence later this year and will be led by researchers at the University of Newcastle in collaboration with the Australasian Leukaemia and Lymphoma Group. Read more here. Watch a Proactive interview with Gary Phillips here.